Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now

Fox Corp (market cap ~ $31B) is positioned to remain far larger than Newsmax ($1.1B) and posted a $690M profit in its September quarter versus Newsmax's $4.1M Q3 net loss; Fox trades at a price-to-sales of 1.8 versus Newsmax's forward sales multiple of 6. Mirum Pharmaceuticals (~$4B market cap) delivered 47% YoY revenue growth in Q3 driven by Livmarli and is acquiring Bluejay Therapeutics (expected close Q1 2026) which could add a Phase 3 asset (brelovitug). The Trade Desk (market cap ~$18.6B) is highlighted as the preferable adtech play given growth prospects from ad-supported connected TV and international expansion. Overall the piece recommends larger, profitable or higher-growth alternatives to Newsmax for investors.

Analysis

Market structure: Scale wins — FOX/FOXA (market cap ~ $31bn) and platform-oriented adtech (TTD, $18.6bn) are positioned to capture a disproportionate share of advertising dollars away from small, politicized outlets like NMAX (market cap ~$1.1bn) because of broader distribution, diversified revenue and lower forward P/S (FOX ~1.8 vs NMAX ~6). Mirum (MIRM, ~$4bn) sits in a different supply-demand dynamic: rare-disease drug demand creates pricing power if clinical/regulatory success occurs; sales growth of +47% YoY signals constrained supply of alternatives and high willingness to pay.

Risk assessment: Tail risks include regulatory action on political media monetization or privacy rules that compress ad yields, Phase 3/approval failure for Mirum or Bluejay assets, and macro-driven ad spend contraction (CPM decline >15%) that would hurt TTD in 3–12 months. Immediate noise (days) from earnings/IPO spikes; short-term (weeks–months) ad-revenue cadence and Q1-2026 M&A close; long-term (12–36 months) outcomes hinge on drug approvals and CTV monetization curves.

Trade implications: Favor long TTD and MIRM vs short NMAX/weak small-cap media; use option structures to control risk (see decisions). Rotate 3–5% of portfolios from small-cap media into adtech and biotech over next 6–12 weeks ahead of Q4 ad reports and Mirum/Bluejay closing. Monitor CPM trends, Fox earnings and political-ad spend as 30–60 day catalysts.

Contrarian angles: Consensus understates acquisition risk for NMAX (private-equity or strategic M&A) which could re-rate; conversely MIRM may be materially priced for flawless execution — a single failed readout could wipe >40% of market cap. Historical parallels: biotech re-rates around binary events; adtech recovers quickly after ad-cycle troughs if programmatic CPMs stabilize. Unintended consequence: faster CTV growth amplifies privacy/regulatory sensitivity, increasing idiosyncratic volatility.

Key Decisions for Investors

• Establish a 2–3% long position in The Trade Desk (TTD) over next 6 weeks; if risk averse, implement a 12-month call spread (buy 12-month ATM call, sell 12-month call 30% OTM) to cap premium. Target horizon 12–24 months with a profit-taking plan at +50% or if ad revenue growth stalls to <5% YoY over two consecutive quarters.
• Initiate a 1% short of Newsmax (NMAX) or buy a 6–9 month put spread (buy 25% OTM put, sell 45% OTM put) sized to risk tolerance; pair with a 1.5–2% long in FOXA to capture relative outperformance. Close within 6–12 months or if NMAX trades below 0.6x current market cap or FOXA re-rates to P/S >2.5.
• Build a 1–2% long position in Mirum (MIRM) before the expected Bluejay deal close in Q1 2026; hedge downside with a 12-month 30% OTM protective put or buy a 18-month LEAP if conviction is high. Set stop-loss at 25% below entry and reassess after the Phase 3 brelovitug readout or regulatory updates — take profits at +60% or on positive Phase 3 news.
• Reallocate 3–5% from small-cap media exposure into adtech (TTD) and biotech (MIRM) over next 4–8 weeks. Monitor two concrete triggers before further augmentation: (1) industry CPM trend data showing QoQ stabilization or improvement in ad spend within 60 days, (2) formal confirmation of Bluejay acquisition close (target: Q1 2026).